Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS) LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...

Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS) LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...

SNS FiRe Conference Names ElpisEremo a 2017 FiReStarter Company SEATTLE, WA--(Marketwired - March 23, 2017) - Strategic News Service™ (SNS) has selected ÉlpisÉremo as a 2017 FiReStarter company to be featured at the 15th annual Future in Review (FiRe) Conference....